Evodia

Evodia (Evodia rutaecarpa / Tetradium ruticarpum)

1. Identity and Botanical Description

Nomenclature and Taxonomy

The plant commonly called Evodia is a tree that comes from China and Korea; it was previously classified in the genus Euodia as Euodia ruticarpa. Its current accepted botanical name is Tetradium ruticarpum (A. Juss.) T.G. Hartley, though the older synonym Evodia rutaecarpa (Juss.) Benth. remains overwhelmingly common in the scientific and medical literature. Both the former genus name and the species name are often misspelled, and the plant usually appears in sources dealing with traditional Chinese medicine as "Evodia(e) rutaecarpa." The plant belongs to the family Rutaceae. The drug material Evodia rutaecarpa is derived from the near-ripe fruit of Euodia rutaecarpa (Juss.) Benth., as well as from two botanical varieties: Euodia rutaecarpa (Juss.) Benth. var. officinalis (Dode) Huang and var. bodinieri (Dode) Huang, all of which are sources of the famous herbal medicine applied for abdominalgia, abdominal distension, vomiting, and diarrhea.

The Chinese herbal name is Wu Zhu Yu (吴茱萸). It is also known as gosyuyu in Japanese. In Japanese, the plant is called 呉茱萸 (Goshuyu) and is used in Kampo preparations such as Goshuyu-tou and Unkei-tou, a group of mixed-herb formulas. In pharmacopoeial and scientific writing it also appears under the names Evodiae Fructus, Tetradii Fructus, and Fructus Evodiae.

Botanical Description and Geographic Origin

E. rutaecarpa is a deciduous tree that grows to a height of about 30 ft (10 m) along the sunny edges of woodlands and in suburban settings as an ornamental. It has long, dark green, shiny leaves and blooms with many small clusters of white flowers in the summer. The fruit, which is the part of the plant used in healing, is reddish when it appears in August and darkens to black by November. The fruit is harvested for medicinal purposes when it is not yet ripe and reddish-brown in color. It is then either used fresh or dried. The plant is native to China, and E. rutaecarpa is native to the northern areas of Korea and China and is cultivated globally.

Official Listing and Common Preparations

The dried fruit of Evodia rutaecarpa (Juss.) Benth has been used as one of the Traditional Chinese Medicines for more than 2,000 years and is officially listed in the Chinese Pharmacopoeia. It has been proven to be effective in the treatment of gastrointestinal disorders, headache, postpartum hemorrhage, amenorrhea, and chill limbs. The dried unripe fruit of Evodia rutaecarpa has been recorded in multiple versions of the Chinese Pharmacopoeia and can be used either alone or in combination with other herbal medicines. Contemporary preparations include:

• Dried whole fruit (decoction): Used in traditional practice as a decoction of dried fruit (1.5–12.0 g daily), placed in water, boiled for 5–10 minutes, strained, and drunk up to three times daily.
• Standardized extracts: Evodia rutaecarpa extract is a concentrated preparation from the nearly ripe fruits of the plant; extracts used in dietary supplements aim to standardize active compounds, principally evodiamine and rutaecarpine (indoloquinazoline alkaloids), plus limonoids (such as limonin) and various quinolone alkaloids.
• Processed ("Zhi") forms: Traditional stir-frying with licorice (Zhi Wu Zhu Yu) measurably shifts metabolite levels. In animal studies, processed Evodia showed attenuated liver injury markers compared with raw Evodia at the same high doses. Processing appears to reduce toxicity signals without eliminating them.
• Topical preparations: Applied externally as pastes or plasters for pain and hypertension management in Chinese traditional practice.
• Capsules: Used in dietary supplement contexts, including in clinical research. In a randomized double-blind clinical trial, participants received Evodia extract in capsule form containing evodiamine 6.75 mg and rutaecarpine 0.66 mg.

2. Traditional and Historical Use

Origins and Core Traditions

Tetradium ruticarpum (Wu Zhu Yu) was first recorded in the Shen Nong Ben Cao Jing, the earliest monograph concerning Traditional Chinese Medicine (TCM), and has been used in numerous herbal formulas for over 2,000 years. Evodia fruit has been used since at least the first century A.D. in traditional Chinese medicine (TCM). It is characterized as having a warm nature and an acrid, bitter, slightly toxic taste, although the fruit is quite fragrant.

Evodia rutaecarpa fruit extract has a rich history in traditional medicine, particularly in Chinese and Korean herbal practices. It is also recognized in Japanese Kampo medicine (漢方), where it is called 呉茱萸 and is an ingredient in named preparations including Goshuyu-tou.

TCM Classification and Therapeutic Properties

In the traditional Chinese medical system, evodia is recognized as a Hot, Acrid herb used to warm the interior and ease pain. It is characterized as having a warm nature and an acrid, bitter, slightly toxic taste. The primary organ channels it is said to enter include the Liver, Spleen, Stomach, and Kidney meridians. The dried unripe fruit of Evodia rutaecarpa could be used either alone or in combination with other herbal medicines to cure headache, epigastric pain, menorrhalgia, dermatophytosis, celialgia, emesis, and appetite disorders.

Traditional Indications

Evodia rutaecarpa is a very popular multi-purpose herb traditionally used in China for the treatment of headaches, abdominal pain, postpartum hemorrhage, dysentery, and amenorrhea. More specifically, traditional applications documented across TCM, Korean, and Japanese practice include:

• Gastrointestinal complaints: It is very commonly used to treat digestive disorders including acid reflux, stomach cramping, ulcers, diarrhea, and dysentery.
• Headache and migraine: Wuzhuyu Tang (WT), a Chinese medicine formula for migraine treatment, is composed of Evodia fruit, ginger, ginseng, and jujube.
• Gynecological conditions: Evodia was frequently prescribed to alleviate coldness in the stomach, relieve menstrual discomfort, and support overall digestive well-being.
• Postpartum hemorrhage and amenorrhea: Rutaecarpine, an alkaloid from Evodia's unripe fruit, is used to treat hypertension, postpartum hemorrhage, dysentery, and amenorrhea as a traditional medicine in Asia.
• Classic multi-herb formula: One of the hallmark remedies utilizing evodia is the classic TCM formula Wu Zhu Yu Tang, designed to harmonize the stomach and liver, calm rebellious Qi, and stop vomiting. This combination includes evodia alongside ginger, ginseng, and jujube.

3. Phytochemistry: Key Constituents and Active Compounds

Overview of Chemical Classes

Approximately 131 chemical compounds, including alkaloids, saponins, phenols, and other compounds, have been isolated from Tetradium plants. Steroids, terpenes, phenolic acids, and alkaloids have been identified from Euodia ruticarpa. The most pharmacologically studied classes are the indoloquinazoline alkaloids and the quinolone alkaloids.

Primary Indoloquinazoline Alkaloids

The three major indole alkaloids are evodiamine (EVO, chemical name: (S)−14-methyl-8,13,13b,14-tetrahydroindolo[2′,3′:3,4]pyrido[2,1-b]quinazolin-5(7H)-one), rutaecarpine (RUT, 8,13-dihydroindolo[2′,3′:3,4]pyrido[2,1-b]quinazolin-5(7H)-one), and dehydroevodiamine (DHE, 14-Methyl-5-oxo-7,8-dihydro-5H-indolo[2′,3′:3,4]-pyrido[2,1-b]quinazolin-14-ium-13-ide). EVO and RUT are the main components for quality control of Evodia rutaecarpa in the Chinese Pharmacopoeia, having been isolated and identified in the early 20th century.

• Evodiamine (EVO): A natural quinolone alkaloid first isolated from the fruit of Evodia rutaecarpa. EVO exhibits poor solubility and low bioavailability. Among the components, alkaloid evodiamine is the most representative active ingredient of Tetradium plants.
• Rutaecarpine (RUT): Rutaecarpine (8,13-dihydroindolo-[2′,3′:3,4]-pyrido [2,1-b] quinazolin-5(7H)-one) is one of the intriguing indolopyridoquinazoline alkaloids isolated from Wu-Chu-Yu.
• Dehydroevodiamine (DHE): DHE is a quinazoline alkaloid isolated from Evodiae Fructus and is one of the main components of the herb. The anti-migratory activity of RUT is less effective than that of EVO, while the neuroprotective activity of DHE is significant. Although DHE has a higher bioavailability, EVO and RUT display better permeability across the blood-brain barrier.

Quinolone Alkaloids

Other key alkaloids identified in the fruit include 1-methyl-2-undecyl-4(1H)-quinolone, evocarpine, 1-methyl-2-[(6Z,9Z)]-6,9-pentadecadienyl-4-(1H)-quinolone, and dihydroevocarpine. Additional alkaloids include evocarpin, 1-methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone, 1-methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone, and synephrine. The quinolone alkaloids from the fruits of E. rutaecarpa have shown some pharmacological activity on human granulocytes and display highly selective antibacterial activity against Helicobacter pylori.

Limonoids

Fourteen compounds have been characterized from the fruit, including evodianinine, rutaecarpine, evodiamine, wuchuyuamide I, hydroxyevodiamine, limonin, daucosterol, triacontanoic acid, nonacosane, and beta-sitosterol. Quinolone alkaloids and limonoids (e.g., limonin) contribute to Evodia's bitterness and may have antimicrobial and gastroprotective roles. Emerging reviews highlight limonoids as under-studied constituents that could influence both efficacy and toxicity.

Additional Minor Compounds

Research indicates that limonin, 1-methyl-2-undecyl-4(1H)-quinolone, and dihydroevocarpine serve as chemical markers for quality control of Evodia rutaecarpa, together with evodiamine. The fruit also contains hortiamine, an alkaloid of safety significance (see Section 7).

4. Established Mechanisms of Action

TRPV1 (Vanilloid Receptor) Agonism

Capsaicin-sensitive sensory neurons are rich in transient receptor potential channel vanilloid type 1 (TRPV1), which plays a fundamental role in pain and is involved in the protective effects on cardiovascular and gastrointestinal systems. TRPV1 can be activated by exogenous agonists such as capsaicin, evodiamine (Evo), and rutaecarpine (Rut), which in turn stimulate CGRP release. Stimulation of calcitonin gene-related peptide (CGRP) release may partially explain the analgesic, cardiovascular and gastrointestinal protective, and anti-obesity activities of Evodia rutaecarpa and its major bioactive components.

Anti-inflammatory Pathways

Evodiamine and rutaecarpine were found to strongly inhibit prostaglandin E2 synthesis from lipopolysaccharide-treated RAW 264.7 cells at 1–10 μM. Evodiamine inhibited cyclooxygenase-2 (COX-2) induction and NF-κB activation. Rutaecarpine is a new class of COX-2 inhibitor partially contributing its in vivo anti-inflammatory activities, as demonstrated in carrageenan-induced paw edema in rats. Evodiamine was found to inhibit hypoxia-induced inflammatory responses by repressing COX-2, COX-2 mRNA, and iNOS expression, as well as PGE₂ release, mediated via dephosphorylation of Akt and p70S6 kinase regulating hypoxia-inducible factor-1 alpha.

Thermogenesis and Adipose Biology

Evodiamine appears to prevent obesity and reduce body fat. The major mechanism eliciting this effect was postulated to be enhancement of uncoupling protein-1 (UCP1) thermogenesis through β3-adrenergic stimulation in brown adipose tissue (BAT). Intragastric administration of evodiamine suppressed neuropeptide Y (NPY) mRNA and peptide levels in the arcuate nucleus of the hypothalamus, which might be one of the mechanisms by which evodiamine exerts fat-loss effects. Regarding rutaecarpine specifically: rutaecarpine was found to promote brown adipocyte mitochondrial biogenesis and thermogenesis in vitro. Chronic rutaecarpine treatment reduced body weight gain and mitigated insulin sensitivity through brown and beige adipocyte thermogenesis. Mechanistic study showed that rutaecarpine activated the energy metabolic pathway AMPK/PGC-1α axis, and deficiency of AMPK abolished the beneficial metabolic phenotype.

Cardiovascular Mechanisms

The cardiovascular actions of rutaecarpine have aroused intense research interest due to its purported inotropic and chronotropic, vasodilatory, anti-platelet activation, anti-oxidant, anti-inflammatory, and lipid-lowering effects. Biochemical and pharmacological studies have illustrated molecular targets of rutaecarpine, such as TRPV1, CGRP, AMPK, ABCA1, and β1-AR.

Cholesterol and Lipid Metabolism

Using a novel interactomics approach, the Nematic Protein Organisation Technique (NPOT), researchers identified ATP-binding cassette transporter A1 (ABCA1) — a key membrane transporter contributing to cholesterol efflux — as a direct binding target of evodiamine. The binding was confirmed by surface plasmon resonance (SPR) experiments. Evodiamine treatment resulted in increased ABCA1 stability, elevated cellular ABCA1 protein levels, and ultimately increased cholesterol efflux from THP-1-derived human macrophages.

Anti-tumor Mechanisms

Evodiamine exerts antitumor effects by inhibiting tumor cell activity and proliferation, blocking the cell cycle, promoting apoptosis and autophagy, and inhibiting the formation of tumor microvasculature. The possible mechanisms related to its anti-cancer activity include its potential action as a modulator of specific receptors such as topoisomerase I, NF-κB, and B-cell lymphoma 2 (Bcl2).

Neurological Mechanisms (DHE)

Dehydroevodiamine has attracted interest for its neuroprotective properties. Novel anticholinesterase and antiamnesic activities of dehydroevodiamine, a constituent of Evodia rutaecarpa, have been documented. The relationship between important transcription factors such as RELA, NF-κB1, SP1, STAT3, and JUN on IL-17, TNF, and MAPK signaling pathways may represent potential mechanisms of Evodia in neurodegenerative and pain conditions.

5. Scientific Evidence by Area of Use

5.1 Gastrointestinal Diseases

As one of the well-known herbal medicines, the effectiveness of Evodia rutaecarpa in treating gastrointestinal diseases has been documented by ancient doctors with long-term clinical practice. Scholars have begun to focus on Evodia and its compounds through modern medical methods. Experimental evidence supports that the three indole alkaloids EVO, RUT, and DHE show therapeutic potential for gastrointestinal diseases, including gastritis, colitis, and colorectal cancer.

Regarding Helicobacter pylori: Japanese researchers have discovered that in test-tube studies, extracts of evodia fruit strongly inhibit the growth of H. pylori. Unlike conventional antibiotics, the extract did not alter the growth patterns of any other intestinal bacteria. Results of one in vitro study showed that the growth of H. pylori reference strains and clinical isolates was inhibited by evodiamine. Limitation: All H. pylori evidence to date is in vitro or in animal models; no published controlled human clinical trials specifically testing Evodia or its isolates against H. pylori infection have been identified in the reviewed literature.

5.2 Obesity, Thermogenesis, and Weight Management

Several studies have demonstrated reduced fat accumulation and body weight after evodiamine supplementation in mice and rats. In a randomized double-blind clinical trial, the body mass index (kg/m²) in premenopausal women was significantly reduced after administration of an Evodia extract in capsules containing evodiamine 6.75 mg and rutaecarpine 0.66 mg. This is one of the very few human trials documented in this domain.

However, evidence in humans is limited in quantity: A randomized crossover study in men tested a single 500 mg evodiamine dose and found no meaningful increase in energy expenditure or fat oxidation at rest or after moderate exercise. That small but carefully performed trial is currently the best direct human test of "thermogenic" claims and does not support acute fat-burning effects. Evodiamine's most repeatable benefits are seen in cells and animals; human evidence is limited and mixed, with at least one negative trial for thermogenesis.

Overall evidence strength: Preclinical (in vitro and animal) evidence is substantial. Human clinical evidence is sparse, with conflicting results. The body of human data is insufficient to draw firm conclusions.

5.3 Cardiovascular Protection

As one of the most representative indolopyridoquinazoline alkaloids of Evodia rutaecarpa, rutaecarpine has broad pharmacological actions in treating various cardiovascular, cerebrovascular, and metabolic diseases. The cardiovascular actions of rutaecarpine include purported inotropic and chronotropic, vasodilatory, anti-platelet activation, anti-oxidant, anti-inflammatory, and lipid-lowering effects.

Regarding platelet aggregation: Rutaecarpine, an alkaloid from Evodia rutaecarpa, has been reported to prevent platelet activation in humans and reduce microvascular thrombosis in mice through the PI3K/Akt/GSK3β signal axis. Rutaecarpine has been shown to have cardiovascular biological effects such as inotropic and chronotropic, vasorelaxant, anti-platelet aggregation and anti-inflammatory effects. The cardiovascular data comes predominantly from in vitro and animal studies, with limited formal human clinical trial data. Evidence strength: Preliminary; mostly preclinical.

5.4 Pain and Analgesia

An earlier study found that oral administration of ethanol extract of Evodia rutaecarpa to mice reduced acetic acid-induced abdominal stretch. Another study confirmed that evodiamine and rutaecarpine were partially responsible for the analgesic effects. Limonin from Evodia rutaecarpa was also found to be analgesic. Evodiamine significantly alleviates mechanical pain and acute visceral neuralgia in mice by reducing peripheral hypersensitivity, significantly affecting neuroprotection, anti-inflammation, and cardiac protection.

However, its analgesic and anti-inflammatory effects still lack credible evidence from well-designed human clinical trials. Evidence strength: Animal model and in vitro data are consistent; human clinical evidence is absent from the reviewed literature.

5.5 Anti-cancer Activity

Growing evidence demonstrates that evodiamine possesses anti-cancer activities both in vitro and in vivo by inhibiting proliferation, invasion and metastasis, and inducing apoptosis of a variety of tumor cell lines. EVO, RUT, and DHE have pharmacological effects including anti-inflammation, anti-tumor, anti-arrhythmic, anti-virus, anti-fibrosis, and metabolic regulation. EVO has an outstanding anti-cancer effect, although clinical trials are still required to further support its therapeutic potential.

Evidence strength: Evidence is confined to preclinical (cell culture and animal) studies. No completed randomized clinical trials in humans evaluating Evodia alkaloids specifically as anti-cancer agents have been identified in the reviewed literature.

5.6 Inflammation and Skin

One notable exception to the dominance of in vitro evidence is a topical skin study: Twice-daily application of 0.1–1% Evodia biomimetic mixture for 2 weeks significantly inhibited erythema after a methyl nicotinate challenge. A single application of 1% Evodia biomimetic mixture also significantly inhibited methyl nicotinate-induced erythema when applied at 60 min before, or within 5 min after, exposure. The Evodia biomimetic mixture was significantly more effective at inhibiting erythema than bisabolol (the active component of chamomile). These results demonstrate that compounds found in E. rutaecarpa (including the indole quinazoline alkaloids) have powerful anti-inflammatory activity when applied topically to human skin. Evidence strength: One controlled human skin study demonstrating topical anti-inflammatory effect; oral anti-inflammatory effects in humans remain unestablished by clinical trials.

5.7 Neurological / Alzheimer's Disease

Evodia rutaecarpa is a Chinese herbal medicine with analgesic and anti-neurodegenerative properties. However, whether Evodia compounds can be applied for the comorbid pain of Alzheimer's disease (AD) and the underlying mechanisms remain unclear. Evodia could simultaneously treat AD comorbid pain through multi-target, multi-component, and multi-pathway mechanisms, and inflammation was identified as an important common phenotype. The relationship between transcription factors such as RELA, NF-κB1, SP1, STAT3, and JUN on IL-17, TNF, and MAPK signaling pathways may represent potential mechanisms.

Evidence strength: Network pharmacology (computational) and preliminary preclinical studies only. No human clinical trial evidence exists in the reviewed literature.

5.8 Liver Disease

Hepatoprotective herbs are used for treating liver diseases and possess potential advantages over conventional therapy. In the past decades, extensive investigations have yielded important insights into the role of natural products from traditional herbal medicines in the management of liver diseases. Both evodiamine and rutaecarpine have been studied for liver-protective effects. Notably, rutaecarpine pretreatment significantly decreased acetaminophen-induced serum ALT/AST activities and hepatic malondialdehyde content, prevented acetaminophen-induced hepatic glutathione depletion, and CYP2E1 expression was decreased in a dose-dependent manner. Rutaecarpine pretreatment also inhibited acetaminophen-induced expression of inflammatory cytokines by inhibiting NF-κB activation by JNK1/2.

Evidence strength: Preclinical (mouse model) only for hepatoprotection. However, note that evodiamine itself carries a documented hepatotoxicity risk at higher doses (see Section 7).

6. Body Systems and Health Areas Associated with Evodia

With respect to the pharmacological actions of evodiamine, attention has been paid to beneficial effects in insults involving cancer, obesity, nociception, inflammation, cardiovascular diseases, Alzheimer's disease, infectious diseases, and thermoregulative effects. A summary of organ-system associations follows:

• Gastrointestinal system: Historically the primary domain; the herb has been applied for abdominalgia, abdominal distension, vomiting, and diarrhea. Indole alkaloids EVO, RUT, and DHE are the major bioactivity compounds.
• Cardiovascular system: Rutaecarpine has broad pharmacological actions in treating various cardiovascular, cerebrovascular, and metabolic diseases.
• Central nervous system: DHE has documented anticholinesterase activity, and the whole herb is used in TCM formulas for headache and migraine.
• Metabolic / adipose tissue: Thermogenic and lipid-modulating effects via TRPV1, UCP1, and AMPK/PGC-1α pathways.
• Immune and infectious: Evodia rutaecarpa is commonly used as an anti-inflammatory herbal remedy in traditional Chinese medicine.
• Reproductive system: Traditional use for dysmenorrhea, amenorrhea, and postpartum hemorrhage.
• Skin: Topical anti-inflammatory applications with documented human evidence.

7. Dosage Forms and Reported Dosages

Dosages documented in the reviewed scientific and pharmacopoeial literature are as follows:

• Chinese Pharmacopoeia (2020 edition): The 2020 edition of the Chinese Pharmacopoeia reported that Evodia rutaecarpa has little toxicity and stipulates an internal dose of 2–5 g (of the dried fruit), with the appropriate amount used externally.
• Decoction (traditional): 1.5–12.0 g daily as a decoction.
• Clinical trial (BMI / weight management): In a randomized double-blind clinical trial, an Evodia extract capsule containing evodiamine 6.75 mg and rutaecarpine 0.66 mg was used.
• Thermogenesis crossover study: A randomized crossover study in men tested a single 500 mg evodiamine dose.
• Topical application (skin study): 0.1–1% Evodia biomimetic mixture applied topically twice daily for 2 weeks, or as a single 1% application.
• Standardized E. rutaecarpa is commonly used in weight-loss formulations; dosages vary with manufacturer and are normally proprietary information.

8. Safety Considerations and Drug Interactions

General Toxicological Profile

The China Pharmacopoeia (2020 Edition) reports that E. rutaecarpa has little toxicity, and adverse reactions caused by its improper use may sometimes occur in a clinical setting. In clinical practice, excessive doses of Evodia rutaecarpa often lead to toxicity, which is mainly manifested as liver toxicity, indicated by significant increases in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Adverse reactions caused by improper use occur in clinical practice. However, the main toxic components and their mechanism of action are still not fully clarified.

Hepatotoxicity

Evodia displays a certain degree of hepatotoxicity, and adverse events have been reported in clinical practice. Evodiamine (EVO) had the most acute toxicity among the six main alkaloids, with an LD50 of 77.8 mg/kg in animal models. EVO can induce an increase in the release of AST, ALT, lactate dehydrogenase (LDH), and alkaline phosphatase; enhance p-p38/p38 expression; and induce mitochondrial swelling, vacuolation, MPT pore opening, and a significant decrease in mitochondrial potential, leading to ATP depletion and cytochrome C release and ultimately triggering cell death. The effective-toxic effects were mainly related to administration time and concentration. Long-term, high-dose administration may induce toxicity; when using EVO or drugs containing EVO to treat diseases, attention should be paid to administration time and dosage.

Cardiac Safety Concerns: IKr (hERG) Channel Inhibition

Evodia extract was found to inhibit hERG channels. The aim of one study was to identify hERG inhibitors in Evodia extract and to investigate their potential proarrhythmic effects. Dehydroevodiamine (DHE) and hortiamine were identified as IKr (rapid delayed rectifier current) inhibitors in Evodia extract by HPLC-microfractionation and subsequent patch-clamp studies on human embryonic kidney cells. DHE and hortiamine inhibited IKr with IC50s of 253.2 ± 26.3 nM and 144.8 ± 35.1 nM, respectively.

In dog ventricular cardiomyocytes, DHE dose-dependently prolonged action potential duration (APD). Early afterdepolarizations (EADs) were seen in 14, 67, 100, and 67% of cells after 0.01, 0.1, 1, and 10 μM DHE, respectively. Depending on the dose, dehydroevodiamine and hortiamine can prolong action potential duration and early afterdepolarizations of cardiomyocytes, eventually leading to arrhythmias. There are also studies indicating that hydroxyrutaecarpine inhibits hERG current by binding to F656 and Y652 sites in the hERG channel, can shorten the inactivation time constant, accelerate channel inactivation, and inhibit the function of the hERG channel.

Two Evodia alkaloids, dehydroevodiamine (DHE) and hortiamine, block the IKr (hERG) potassium channel at nanomolar concentrations in vitro and prolong cardiac repolarization in animal models, a pattern associated with QT prolongation and arrhythmia risk. E. rutaecarpa contains small amounts of synephrine, and use with caution is warranted in individuals with heart conditions such as hypertension or arrhythmias.

Nephrotoxicity

Current research found that EVO could have toxic effects, including hepatotoxicity, nephrotoxicity, and cardiac toxicity. Evodia Fructus's nephrotoxic effects primarily stem from renal cell death and oxidative stress.

Drug Metabolism Interactions (CYP Enzymes)

Research on Evodia rutaecarpa and its primary alkaloids highlights their impact on drug metabolism. The traditional herbal medicine Wu-chu-yu-tang was studied for its effects on mouse liver enzyme activities involved in drug metabolism. A significant increase in CYP1a2 activity was observed, suggesting potential drug interactions. Among Wu-chu-yu-tang's components, only Evodiae Fructus extract led to an increase in liver enzyme activity and CYP1a2 protein levels. Rutaecarpine was identified as the active ingredient responsible for this effect. Evodia constituents can interact with hepatic enzymes in vitro, creating the potential for interactions with drugs metabolized by cytochrome P450 enzymes, including CYP1A2, CYP3A4, and others.

Processing and Dose Dependency

Traditional stir-frying with licorice (Zhi Wu Zhu Yu) measurably shifts metabolite levels. In animal studies, processed Evodia showed attenuated liver injury markers and altered bile acid and steroid pathways compared with raw Evodia at the same high doses. Processing appears to reduce toxicity signals without eliminating them, underscoring why product choice matters.

Pregnancy and Lactation

Evodia should not be used in pregnancy or lactation based on available safety data.

Summary of Safety Context

Current research confirms that EVO can have toxic effects, including hepatotoxicity, nephrotoxicity, and cardiac toxicity. The proarrhythmic potential of DHE and hortiamine, established through in vitro and in vivo animal research, is a mechanistically plausible concern, particularly for individuals with pre-existing cardiac conduction abnormalities or those taking other QT-prolonging agents. The body of research on Evodia rutaecarpa reinforces the need for awareness of possible drug interactions when using traditional herbal medicines containing this plant.

References

• Chen L et al. "Major Indole Alkaloids in Evodia Rutaecarpa: The Latest Insights and Review of Their Impact on Gastrointestinal Diseases." Biomedicine & Pharmacotherapy, 2023. ScienceDirect.
• Southall MD et al. "Anti-inflammatory activity in skin by biomimetic of Evodia rutaecarpa extract from traditional Chinese medicine." PubMed, 2006.
• ScienceDirect Topics: Tetradium ruticarpum — Overview.
• PMC: "Active Ingredients from Euodia ruticarpa Steam Distilled Essential Oil Inhibit PC-3 Prostate Cancer Cell Growth." PMC8928987.
• PubMed: "Studies on the chemical constituents of Evodia rutaecarpa (Juss.) Benth." PMID 15563061.
• PubMed: "Evodia rutaecarpa and Three Major Alkaloids Abrogate Influenza A Virus (H1N1)-Induced Chemokines Production and Cell Migration." PMID 21799692.
• PMC: "Potential active compounds and common mechanisms of Evodia rutaecarpa for Alzheimer's disease comorbid pain by network pharmacology analysis." PMC10388172.
• PubMed: "Rutaecarpine: A promising cardiovascular protective alkaloid from Evodia rutaecarpa (Wu Zhu Yu)." PMID 30616017.
• PMC: "Evodiamine: A Novel Anti-Cancer Alkaloid from Evodia rutaecarpa." PMC6254303.
• Wikipedia: Tetradium ruticarpum.
• ScienceDirect: "Evodiamine and rutaecarpine from Tetradium ruticarpum in the treatment of liver diseases." Phytomedicine, 2020.
• Encyclopedia.com: Evodia Fruit.
• MDPI Molecules: "Pharmacological Actions of Multi-Target-Directed Evodiamine." 2013.
• PMC / Scientific Reports: "Novel interactomics approach identifies ABCA1 as direct target of evodiamine." PMC6056500.
• PMC: "Rutaecarpine Promotes Adipose Thermogenesis and Protects against HFD-Induced Obesity via AMPK/PGC-1α Pathway." PMC9027001.
• International Journal of Nanomedicine: "Evodiamine: A Extremely Potential Drug Development Candidate of Alkaloids from Evodia rutaecarpa." 2024.
• PMC: "Analysis of the Molecular Mechanism of Evodia rutaecarpa Fruit in the Treatment of Nasopharyngeal Carcinoma Using Network Pharmacology and Molecular Docking." PMC9020960.
• PMC: "Rutaecarpine Protects against Acetaminophen-Induced Acute Liver Injury in Mice by Activating Antioxidant Enzymes." PMC7827407.
• PMC: "Simultaneous Quantification of Limonin, Two Indolequinazoline Alkaloids, and Four Quinolone Alkaloids in Evodia rutaecarpa by HPLC-DAD Method." PMC3664498.
• PubMed: "Evodiamine: A Privileged Structure with Broad-ranging Biological Activities." PMID 35379148.
• ScienceDirect / Pharmacological Research: "Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are IKr blockers with proarrhythmic effects in vitro and in vivo." Baburin et al., 2018.
• ScienceDirect: "Antiarrhythmic effects of dehydroevodiamine in isolated human myocardium and cardiomyocytes." 2014.
• PMC: "Pharmacological Effects of Rutaecarpine as a Cardiovascular Protective Agent." PMC6257227.
• PMC: "Anti-inflammatory and anti-infectious effects of Evodia rutaecarpa (Wuzhuyu) and its major bioactive components." PMC3046897.
• PMC: "Evodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation." PMC8036659.
• PMC: "The pharmacokinetics profiles, pharmacological properties, and toxicological risks of dehydroevodiamine: A review." PMC9715618.
• Frontiers in Pharmacology: "Euodiae Fructus: a review of botany, application, processing, phytochemistry, quality control, pharmacology, and toxicology." 2025.
• GlobinMed: Evodia rutaecarpa herb profile.